Corinne Haioun

Henri Mondor Hospital And University Paris Est
Creteil, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 206 publications

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 06, 2026

[Erratum to "Breast implants and cancer: Anaplastic large cell lymphoma associated with breast implants" [Annales de Chirurgie Plastique Esthétique, 70/6 (November 2025), pp. 572-80]].

[Erratum to "Breast implants and cancer: Anaplastic large cell lymphoma associated with breast implants" [Annales de Chirurgie Plastique Esthétique, 70/6 (November 2025), pp. 572-80]].

Journal: Annales de chirurgie plastique et esthetique

Published: January 31, 2026

Breast implants and cancer: Anaplastic large cell lymphoma in breast implants

Breast implants and cancer: Anaplastic large cell lymphoma in breast implants

Journal: Annales de chirurgie plastique et esthetique

Published: January 31, 2026

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 02, 2025

Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.

Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.

Journal: Blood advances

Published: May 23, 2025

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 20, 2025

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 20, 2025

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.

Journal: Hematological oncology

Published: April 01, 2025

Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines.

Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 17, 2025

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.

Journal: Haematologica

Published: December 10, 2024

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Journal: Blood advances

Published: December 10, 2024

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

Journal: British journal of haematology

Published: December 03, 2024

Showing 1-12 of 206

Last Updated: 09/26/2026